Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

NCT05804656 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-12-12

No results posted yet for this study

Summary

A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines

Conditions

  • Glabellar Lines

Interventions

DRUG

CKDB-501A

Intramuscular injection CKDB-501A

DRUG

Botox®

Intramuscular injection Botox®

Sponsors & Collaborators

  • CKD Bio Corporation

    lead INDUSTRY

Principal Investigators

  • Beomjoon Kim · Chung-Ang University Hosptial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-13
Primary Completion
2023-08-29
Completion
2023-11-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05804656 on ClinicalTrials.gov